PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s

Vanguard's tech-heavy portfolio delivered stronger five-year returns despite higher volatility, whil

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zac

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Prio

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today r

Bank of New York Mellon Corp lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDA

Fifth Third Bancorp grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 3,937.3% d

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today re

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 202

FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2

PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026

Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average tradin

Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, roy

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today rep

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today re

Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, levera

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Confer

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist"

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Pat

Under the terms of its January 2024 worldwide license and collaboration agreement with Takeda, the s

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Contro

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its im

Rusfertide plus current standard of care more than doubled clinical response rates across high- and

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ

  On Tuesday, 951 companies hit new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Wednesday, 216 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched

Upgrades

    Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.

    On Friday morning, 154 companies achieved new highs for the year.

  Thursday's morning session saw 167 companies set new 52-week highs.

  This morning 161 companies reached new 52-week highs.

    This morning 132 companies reached new 52-week highs.

    Monday's morning session saw 49 companies set new 52-week highs.

  This morning 94 companies set new 52-week highs.

    During Wednesday's morning trading, 251 companies set new 52-week highs.

    Tuesday morning saw 244 companies set new 52-week highs.